La cadena de opciones muestra datos clave de las opciones de acciones de SI-BONE a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para SI-BONE..

SI-BONE (NASDAQ:SIBN) Bolsa, Cadena de Opciones

SI-BONE

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEON

ANIP

BBAI

BLRX

CFFI

DOYU

GCTK

LUXH

PMAX

QUBT

RIME

SANG

SIBN

SLXN

SOBR

SONM

TNXP

WHLR

TSMC y otras acciones destacaron en el premercado tras reportar ganancias récord. Descubre los mayores ganadores y perdedores.

Acciones de Taiwan Semiconductor (TSM) suben alrededor del 5%; 20 acciones en movimiento en el premercado de EE.UU.

SI-BONE Inc

Si-Bone ( ($SIBN) ) has released its Q3 earnings. Here is a breakdown of the information Si-Bone presented to its investors. SI-BONE, Inc., a leadi...

SI-BONE Reports Strong Q3 Growth and Optimistic Outlook

JMP Securities analyst David Turkaly reiterated a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $32.00. David Turk...

SI-Bone's Strong Sales Growth and Innovative Product Pipeline Support Continued Buy Rating

Analyst Drew Ranieri from Morgan Stanley maintained a Buy rating on SI-Bone (SIBN – Research Report) and keeping the price target at $19.00. Drew R...

SI-Bone's Resilience and Growth Potential Amid Challenges: Analyst Maintains Buy Rating

Truist raised the firm's price target on SI-Bone (SIBN) to $18 from $16 and keeps a Buy rating on the shares after its Q3 results. The quarter's po...

SI-Bone price target raised to $18 from $16 at Truist

Morgan Stanley assumed coverage of SI-Bone (SIBN) with an Overweight rating and a price target of $15, down from $19. The firm's lower target facto...

SI-Bone assumed with an Overweight at Morgan Stanley

SI-BONE announces Q4 preliminary worldwide revenue between $48.8 - $49M

Ended the quarter with ~1,390 active physicians in the U.S., representing ~23% growth; Cash and marketable securities of ~$150 million, implying ne...

SI-Bone sees Q4 revenue $48.8M-$49M, consensus $46.89M

Needham analyst David Saxon maintained a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $19.00. David Saxon has giv...

SI-Bone's Strong Performance and Growth Prospects Earn 'Buy' Rating from David Saxon

Truist Financial analyst Richard Newitter maintained a Buy rating on SI-Bone (SIBN – Research Report) today. The company's shares closed yesterday ...

Truist Financial Keeps Their Buy Rating on SI-Bone (SIBN)

Next Century Growth Investors Q4 2024 Commentary

ADBE

ALHC

AMZN

APPF

ATRO

AVAV

AVPT

AXON

BWIN

CAVA

CBLL

CDNA

DXCM

GDYN

GWRE

INOD

KIDS

KRUS

LNTH

MNDY

MPTI

MPWR

MYRG

NSSC

NVDA

ODFL

PCTY

PEGA

PNFP

PYCR

RXST

SAIA

SARO

SPSC

TMDX

TNDM

TOST

TSLA

USAP

VERX

VRRM

VRTX

WDAY

WEAV

WING

XMTR

Earnings

Press Releases

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024

SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024

Health Care

SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System

SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

General

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance

SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024

Comments

SI-BONE

SI-BONE (SIBN) Opciones

SI-BONE (NASDAQ:SIBN) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL